Obesity
CV
+4
Aug 18, 2026
•
14 min read
It's Already on Every Panel. Nobody Reads It.
Remnant cholesterol costs nothing to calculate and predicts events when LDL no longer does. Its first real drug just proved it can prevent pancreatitis, and then failed to move plaque.
Coverage
+4
Aug 8, 2026
•
13 min read
Every First Claim Is Denied. That's the Design.
One month into the Medicare GLP-1 Bridge, the denial at the counter isn't a coverage decision — and CMS built no appeals process for the ones that are.
GLP1
+4
Aug 4, 2026
•
12 min read
Retatrutide Won Twice. The Heart Data Didn't.
TRIUMPH-2 and TRIUMPH-3 both hit — 20.8% in type 2 diabetes, 22.6% with established cardiovascular disease. Then there's the MACE table.
GLP1
+3
Jul 28, 2026
•
4 min read
The Triple Agonist, in Plain Numbers
Retatrutide is posting some of the largest weight-loss numbers the incretin class has seen. Here's what the data actually says — and the two things to watch before the headline. Free cheat sheet inside.
GLP1
+2
Jul 21, 2026
•
4 min read
I Put Twelve GLP-1 Trials on One Page
The evidence that actually holds up in 2026 — weight loss, heart, kidney, muscle, and the myths that should have died already. Free one-page reference inside.
GLP1
+2
Jul 11, 2026
•
6 min read
SPECIAL EDITION: Nobody Asked.
A new JAMA secret-shopper study bought 45 GLP-1 prescriptions online. Most arrived in a day. Some in under 5 minutes. Almost none asked the questions that keep patients safe. I have watched this happen from the inside, and I know exactly why.
GLP1
+1
Jul 7, 2026
•
3 min read
I Built a Live Index of Every Obesity Drug Trial
The pipeline moves faster than any newsletter can. So I stopped trying to summarize it and built something that updates itself.
GLP1
+2
Jul 4, 2026
•
11 min read
Obesity Medicine Stopped Being a Horse Race
Nine drugs, four receptors, and two new pills into 2026, the field is quietly reorganizing around a better question. Not how much weight. Which disease.
GLP1
+2
Jun 23, 2026
•
8 min read
Medicare Will Pay for Wegovy Now. Here's the Catch.
Starting July 1, eligible Medicare patients get Wegovy, Zepbound, or the new pill Foundayo for $50 a month. The program is real. It's transformative. And almost everything you've read about it is slightly wrong.
Obesity
+1
Jun 19, 2026
•
9 min read
Obesity Care: I Was Wrong
I argued for fixing the system from the inside. The evidence changed my mind.
GLP1
+2
Jun 16, 2026
•
9 min read
Glucagon Doesn't Win the Scale. It Wins the Liver.
Survodutide and pemvidutide keep landing below 20% on body weight — while clearing liver fat at rates no pure GLP-1 can touch. A dispatch on the ADA 2026 readouts, and the case for grading incretins on the right organ.
GLP1
+2
May 19, 2026
•
13 min read
ECO 2026: The Maintenance Era Begins.
Istanbul gave us the answers we have been waiting for. Obesity is now being treated like every other chronic disease — and the data is on the right side of history.
Obesity
+1
May 16, 2026
•
7 min read
The One Thing. Move.
If I could ask every patient, every reader, every person I know to change just one thing about their daily life — this would be it.
GLP1
+2
Apr 22, 2026
•
17 min read
Before or After? The GLP-1 and Surgery Sequencing Question
The science of sequencing GLP-1 therapy and bariatric surgery — and why the answer is more complicated than anyone wants to admit.
GLP1
+3
Mar 27, 2026
•
15 min read
What Semaglutide Teaches Us About How GLP-1 Regulates Body Weight
It's not the injection site. It's not gut GLP-1. It's not thermogenesis. The pharmacokinetics of semaglutide across multiple trials offer a surprisingly clean window into how this molecule — and this biology — actually works.
GLP1
+2
Mar 21, 2026
•
13 min read
SPECIAL EDITION: When the Drug Stops Working (Because You Stopped the Drug)
A new BMJ Medicine analysis quantifies what happens to cardiovascular risk after GLP-1 discontinuation. The numbers are striking. The framing some are applying to them is wrong.
GLP1
+3
Mar 19, 2026
•
14 min read
The Drug That May Redefine What's Possible
Retatrutide may be the first pharmacotherapy to approach bariatric surgery–level weight loss. Phase 3 data now confirm what phase 2 only suggested: this is a categorically different molecule.
GLP1
+1
Mar 6, 2026
•
20 min read
Why Weight Returns After Stopping GLP-1 Therapy: The Biology You Need to Understand
Across randomized trials, stopping GLP-1/dual incretin therapy is typically followed by clinically meaningful weight regain and loss of cardiometabolic gains—often within months—highlighting obesity as a chronic, relapsing condition.
